Your browser doesn't support javascript.
loading
Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
William E Matchett; Vineet Joag; James Michael Stolley; Frances K Shephard; Clare F Quarnstrom; Clayton K Mickelson; Sathi Wijeyesinghe; Andrew G Soerens; Samuel Becker; Joshua M Thiede; Eyob Weyu; Jennifer Walter; Michelle N Vu; Vineet D Menachery; Tyler D. Bold; Vaiva Vezys; Marc K Jenkins; Ryan A. Langlois; David Masopust.
Afiliação
  • William E Matchett; University of Minnesota
  • Vineet Joag; University of Minnesota
  • James Michael Stolley; University of Minnesota
  • Frances K Shephard; University of Minnesota
  • Clare F Quarnstrom; University of Minnesota
  • Clayton K Mickelson; University of Minnesota
  • Sathi Wijeyesinghe; University of Minnesota
  • Andrew G Soerens; University of Minnesota
  • Samuel Becker; University of Minnesota
  • Joshua M Thiede; University of Minnesota
  • Eyob Weyu; University of Minnesota
  • Jennifer Walter; University of Minnesota
  • Michelle N Vu; University of Texas Medical Branch at Galveston
  • Vineet D Menachery; University of Texas Medical Branch
  • Tyler D. Bold; University of Minnesota
  • Vaiva Vezys; University of Minnesota
  • Marc K Jenkins; University of Minnesota
  • Ryan A. Langlois; University of Minnesota
  • David Masopust; University of Minnesota
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-441518
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing antibodies target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with HAd5 expressing the nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and k18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral antigens, even if they are not a target of neutralizing antibodies, to broaden epitope coverage and immune effector mechanisms.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...